Ipamorelin & CJC-1295 Stack - Advanced Dual-Pathway GH Secretagogue Combination

The Ipamorelin & CJC-1295 (Mod GRF 1-29) stack is one of the most widely studied growth hormone–secretagogue combinations in modern peptide research. Together, these two peptides target complementary pathways within the hypothalamic–pituitary–somatotropic axis, making the stack a powerful model for exploring growth hormone pulsatility, IGF-1 regulation, metabolic signaling, and regenerative biology.

• CJC-1295 (Mod GRF 1-29) is a modified GHRH analog designed to support short, natural GH pulse patterns.
• Ipamorelin is a selective GHS-R (ghrelin receptor) agonist known for GH-specific stimulation with minimal off-target hormonal activity.

This combination provides a reliable, synergistic platform for laboratory studies focused on endocrine function, metabolic processes, and cellular recovery mechanisms.

Key Research Benefits of Ipamorelin & CJC-1295 (Mod GRF 1-29)

• Synergistic GH Release - Dual activation of the GHRH and ghrelin pathways results in a stronger and more comprehensive GH response in controlled research settings.
• Enhanced IGF-1 Pathway Exploration - The combination offers a robust model for investigating IGF-1 production and its downstream biological effects.
• Metabolic & Body Composition Insights - Frequently used in studies examining lipolysis, nutrient partitioning, lean-mass signaling, and mitochondrial energy regulation.
• Improved GH Pulsatility - CJC-1295 (Mod GRF 1-29) supports natural GH pulse patterns, while Ipamorelin amplifies peak GH responses—ideal for studying physiological secretion dynamics.
• Regeneration & Recovery Models - Useful for research on tissue repair, cellular recovery, and age-related changes in GH/IGF-1 function.
• Clean, Targeted Mechanisms - Ipamorelin's selective receptor profile helps maintain consistent and controlled outcomes in endocrine research.